OBJECTIVES: To perform a QoL evaluation in patients with mBC in treatment with chemotherapy with/without bevacizumab according with treatment response. METHODS: We included 48 patients with mBC in two groups, 28 without disease progression (NP) median age 55.19 years (51.2-59.18) and 5.6 years (3.07-8.13) of disease evolution; and 20 with disease progression (DP) median age 57.7 years (50.9-64.5) and 3.74 years (2.48-4.99) of evolution. We applied to both groups the Functional Assessment of Cancer Treatment - Biological Response Modifier questionnaire. The dimension between the five answers categories (Not at all, A little bit, Some-what, Quite a bit, Very much) was quantified using the Karnofsky scale in order to construct a QoL index. A one year QoL evaluation was done with a simulation using a Markov Model, the model included three health status: remission, relapse and dead. The probability of progression and dead was obtained of the data reported with the use of Placitaxel w/wo Bevacizumab (Miller K. 2007) assuming an exponential behavior. RESULTS: The 78.2% (75%-82%) of patients with NP reported a good or very good status, compared with 23.6% (14%-34%) of patients with DP. The global QoL reported by patients with NP was 80.66% (78.99%-82.34%) significantly greater than 66.97% (66.97%-69.69%) obtained form patients with DP (Mann-Whitney<0.0001). The QoL results showed differences in the use of chemotherapy, there was a greater improve in QoL mBC patients with Paclitaxel+Bevacizumab than with Placitaxel alone: 0.77 vs. 0.745 p=0.017.CONCLUSIONS: The QoL level reported by patients with mBC is determined by the presence or absence of disease progression, better QoL no disease progression. With these data, it is possible that the use of Paclitaxel+Bevacizumab, improves QoL and might be, it’ll related with less social and familiar disturbances.